Microtubule polymerization induced by iridium‐fullerene photosensitizers for cancer immunotherapy via dual‐reactive oxygen species regulation strategy

Microtubule polymerization induced by iridium‐fullerene photosensitizers for cancer immunotherapy via dual‐reactive oxygen species regulation strategy

Abstract Microtubules (MTs) are key players in cell division, migration, and signaling, and they are regarded as important targets for cancer treatment. In this work, two fullerene (C60)‐functionalized Ir(III) complexes (Ir‐C601 and Ir‐C602) are rationally designed as dual reactive oxygen species (R...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiao‐Xiao Chen, Kun Peng, Xi Chen, Zheng‐Yin Pan, Qing‐Hua Shen, Yu‐Yi Ling, Jian‐Zhang Zhao, Cai‐Ping Tan
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Aggregate
Subjects:
anticancer
fullerene
iridium complexes
microtubule
photo‐immunotherapy
Online Access:https://doi.org/10.1002/agt2.623
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Microtubules (MTs) are key players in cell division, migration, and signaling, and they are regarded as important targets for cancer treatment. In this work, two fullerene (C60)‐functionalized Ir(III) complexes (Ir‐C601 and Ir‐C602) are rationally designed as dual reactive oxygen species (ROS) regulators and MT‐targeted Type I/II photosensitizers. In the dark, Ir‐C601 and Ir‐C602 serve as ROS scavengers to eliminate O2•− and •OH, consequently reducing the dark cytotoxicity and reversing dysfunctional T cells. Due to the efficiently populated C60‐localized intraligand triplet state, Ir‐C601 and Ir‐C602 can be excited by green light (525 nm) to produce O2•− and •OONO− (Type I) and 1O2 (Type II) to overcome tumor hypoxia. Moreover, Ir‐C601 is also able to photooxidize tubulin, consequently interfering with the cellular cytoskeleton structures, inducing immunogenic cell death and inhibiting cell proliferation and migration. Finally, Ir‐C601 exhibits promising photo‐immunotherapeutic effects both in vitro and in vivo. In all, we report here the first MT stabilizing photosensitizer performing through Type I/II photodynamic therapy pathways, which provides insights into the rational design of new photo‐immunotherapeutic agents targeting specific biomolecules.
ISSN:2692-4560

Similar Items